H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution associated with the equity raise for the target drop.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Signs Lease Agreement in Houston
- Plus Therapeutics provides update on CNSide Diagnostic platform launch
- PSTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Buy Rating for Plus Therapeutics Driven by Strategic Advancements and Market Expansion for CNSide Test
- Buy Rating for Plus Therapeutics Driven by CNSide Coverage and Promising Pipeline Developments